Abbott Laboratories Quarterly Cash Flow Statement
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Abbott Laboratories free cash flow
In the quarter ended Mar 31, 2026, Abbott Laboratories generated $1.31 billion of operating cash flow and spent $399.0 million on capital expenditures. That left free cash flow of $916.0 million, a free-cash-flow margin of 8.2% of revenue. Free cash flow was down 1.8% from the prior year's $933.0 million.
Abbott Laboratories returned $1.28 billion to shareholders: $1.10 billion in dividends and $180.0 million in share repurchases, equal to 140% of free cash flow. Free cash flow covered dividend payments 0.8 times.
Summary generated from market data by MetaCap's automated system. Methodology
Abbott Laboratories cash flow statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.08B | 1.78B | 1.64B | 1.78B | 1.32B | 9.23B | 1.65B | 1.30B | 1.23B | 1.59B | 1.44B | 1.38B |
| Net Income growth (YoY) | -18.72% | -80.76% | -0.12% | +36.64% | +8.16% | +478.98% | +14.62% | -5.31% | -7.06% | +54.31% | +0.07% | -31.86% |
| Depreciation & Amortization | 381.00M | 370.00M | 371.00M | 357.00M | 336.00M | 342.00M | 331.00M | 334.00M | 333.00M | 332.00M | 328.00M | 302.00M |
| Stock-Based Compensation | 317.00M | 113.00M | 120.00M | 142.00M | 289.00M | 111.00M | 117.00M | 141.00M | 304.00M | 114.00M | 117.00M | 132.00M |
| Change in Working Capital | -462.00M | 456.00M | 11.00M | -407.00M | -517.00M | 77.00M | 163.00M | -428.00M | -561.00M | 363.00M | -321.00M | -444.00M |
| Operating Cash Flow | 1.31B | 3.31B | 2.79B | 2.05B | 1.42B | 2.87B | 2.71B | 1.96B | 1.02B | 3.04B | 1.88B | 1.20B |
| Capital Expenditures | -399.00M | -689.00M | -496.00M | -502.00M | -484.00M | -720.00M | -556.00M | -533.00M | -398.00M | -755.00M | -560.00M | -507.00M |
| Investing Cash Flow | -20.32B | -913.00M | -457.00M | -582.00M | -470.00M | -866.00M | -594.00M | -453.00M | -425.00M | -824.00M | -634.00M | -1.21B |
| Dividends Paid | -1.10B | -1.03B | -1.03B | -1.03B | -1.03B | -958.00M | -960.00M | -961.00M | -957.00M | -888.00M | -888.00M | -890.00M |
| Share Repurchases | -180.00M | -302.00M | -305.00M | -6.00M | -280.00M | -315.00M | -751.00M | -3.00M | -226.00M | -259.00M | -2.00M | -426.00M |
| Debt Issued | 19.86B | — | 0 | 2.00M | 1.00M | — | 1.00M | 221.00M | 0 | — | 0 | — |
| Debt Repaid | -1.42B | — | -501.00M | -1.00M | -1.00B | — | -2.00M | -18.00M | 0 | — | -1.45B | -2.00M |
| Financing Cash Flow | 17.31B | -1.40B | -1.76B | -1.10B | -2.06B | -1.86B | -1.58B | -791.00M | -1.18B | -2.05B | -2.34B | -1.29B |
| Net Change in Cash | -1.72B | 1.01B | 560.00M | 419.00M | -1.08B | 58.00M | 571.00M | 703.00M | -612.00M | 187.00M | -1.13B | -1.33B |
| Free Cash Flow | 916.00M | 2.63B | 2.29B | 1.54B | 933.00M | 2.15B | 2.15B | 1.43B | 627.00M | 2.28B | 1.32B | 696.00M |
This table shows 12 quarterly periods of Abbott Laboratories's cash flow statement, from Q1 2026 back to Q2 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABT's reporting calendar. What is a cash flow statement?